首页> 外文期刊>Journal of applied physiology >Systemic low-dose aspirin and clopidogrel independently attenuate reflex cutaneous vasodilation in middle-aged humans.
【24h】

Systemic low-dose aspirin and clopidogrel independently attenuate reflex cutaneous vasodilation in middle-aged humans.

机译:全身低剂量阿司匹林和氯吡格雷可独立减弱中年人的反射性皮肤血管舒张作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic systemic platelet cyclooxygenase (COX) inhibition with low-dose aspirin [acetylsalicylic acid (ASA)] significantly attenuates reflex cutaneous vasodilation in middle-aged humans, whereas acute, localized, nonisoform-specific inhibition of vascular COX with intradermal administration of ketorolac does not alter skin blood flow during hyperthermia. Taken together, these data suggest that platelets may be involved in reflex cutaneous vasodilation, and this response is inhibited with systemic pharmacological platelet inhibition. We hypothesized that, similar to ASA, specific platelet ADP receptor inhibition with clopidogrel would attenuate reflex vasodilation in middle-aged skin. In a double-blind crossover design, 10 subjects (53+/-2 yr) were instrumented with four microdialysis fibers for localized drug administration and heated to increase body core temperature [oral temperature (Tor)] 1 degrees C during no systemic drug (ND), and after 7 days of systemic ASA (81 mg) and clopidogrel (75 mg) treatment. Skin blood flow (SkBF) was measured using laser-Doppler flowmetry over each site assigned as 1) control, 2) nitric oxide synthase inhibited (NOS-I; 10 mM NG-nitro-L-arginine methyl ester), 3) COX inhibited (COX-I; 10 mM ketorolac), and 4) NOS-I+COX-I. Data were normalized and presented as a percentage of maximal cutaneous vascular conductance (%CVCmax; 28 mM sodium nitroprusside+local heating to 43 degrees C). During ND conditions, SkBF with change (Delta) in Tor=1.0 degrees C was 56+/-3% CVCmax. Systemic low-dose ASA and clopidogrel both attenuated reflex vasodilation (ASA: 43+/-3; clopidogrel: 32+/-3% CVCmax; both P<0.001). In all trials, localized COX-I did not alter SkBF during significant hyperthermia (ND: 56+/-7; ASA: 43+/-5; clopidogrel: 35+/-5% CVCmax; all P>0.05). NOS-I attenuated vasodilation in ND and ASA (ND: 28+/-6; ASA: 25+/-4% CVCmax; both P<0.001), but not with clopidogrel (27+/-4% CVCmax; P>0.05). NOS-I+COX-I was not different compared with NOS-I alone in either systemic treatment condition. Both systemic ASA and clopidogrel reduced the time required to increase Tor 1 degrees C (ND: 58+/-3 vs. ASA: 45+/-2; clopidogrel: 39+/-2 min; both P<0.001). ASA-induced COX and specific platelet ADP receptor inhibition attenuate reflex vasodilation, suggesting platelet involvement in reflex vasodilation through the release of vasodilating factors.
机译:低剂量阿司匹林[乙酰水杨酸(ASA)]对慢性全身性血小板环氧化酶(COX)的抑制作用明显减弱了中年人的反射性皮肤血管舒张作用,而皮内注射酮咯酸对急性,局部,非异构体特异性的血管COX抑制作用却没有在热疗期间改变皮肤的血液流动。综上所述,这些数据表明血小板可能参与了反射性皮肤血管舒张,并且这种反应被全身性药理血小板抑制所抑制。我们假设,与ASA相似,氯吡格雷对特定血小板ADP受体的抑制作用会减弱中年皮肤的反射性血管舒张作用。在双盲交叉设计中,为10位受试者(53 +/- 2年)配备了四根微透析纤维,用于局部给药,并加热以在无全身药物的情况下将体芯温度[口腔温度(Tor)]升高1摄氏度( ND),以及全身性ASA(81 mg)和氯吡格雷(75 mg)治疗7天后。使用激光多普勒血流仪在分配为1)对照的每个部位上测量皮肤血​​流量(SkBF),2)一氧化氮合酶被抑制(NOS-1; 10 mM NG-硝基-L-精氨酸甲酯),3)COX被抑制(COX-1; 10 mM酮咯酸),和4)NOS-1 + COX-1。将数据标准化并表示为最大皮肤血管电导率的百分比(%CVCmax; 28 mM硝普钠+加热至43摄氏度的局部加热)。在ND条件下,Tor = 1.0℃下具有变化Δ的SkBF为56 +/- 3%CVCmax。全身低剂量ASA和氯吡格雷均减弱了反射性血管舒张作用(ASA:43 +/- 3;氯吡格雷:32 +/- 3%CVCmax;两者均P <0.001)。在所有试验中,局部COX-1在明显的体温过高时均未改变SkBF(ND:56 +/- 7; ASA:43 +/- 5;氯吡格雷:35 +/- 5%CVCmax;所有P> 0.05)。 NOS-1减弱了ND和ASA的血管舒张作用(ND:28 +/- 6; ASA:25 +/- 4%CVCmax;两者均P <0.001),但氯吡格雷不起作用(27 +/- 4%CVCmax; P> 0.05 )。在任一全身治疗条件下,NOS-1 + COX-1与单独的NOS-1相比均无差异。全身性ASA和氯吡格雷均减少了增加Tor 1摄氏度所需的时间(ND:58 +/- 3 vs. ASA:45 +/- 2;氯吡格雷:39 +/- 2 min;均P <0.001)。 ASA诱导的COX和特定的血小板ADP受体抑制作用减弱了反射性血管舒张,提示血小板通过释放血管舒张因子而参与反射性血管舒张。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号